Pemgarda (pemivibart)

Kathryn Dzintars, Pharm.D., BCPS



  • The U.S. FDA issued an emergency use authorization (EUA) for the emergency use of pemivibart (Pemgarda) for pre-exposure prophylaxis of COVID-19 disease in adults and adolescents (12 years of age and older, weighing at least 40kg)
    • Subjects should NOT be currently infected with SARS-CoV-2, and have not had recent exposure to an individual infected with SARS-CoV-2 and
    • Subjects have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications and are considered unlikely to mount an adequate immune response to COVID-19 vaccination.
  • Pemivibart is NOT authorized for:

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: May 20, 2024